{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:19:20Z","timestamp":1790007560499,"version":"4.0.1"},"reference-count":37,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,1,31]]},"DOI":"10.1248\/bpb.b24-00737","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:13:52Z","timestamp":1738275232000},"page":"65-74","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological Profile of NCP-322, a Novel G Protein-Coupled Receptor 119 Agonist, as an Orally Active Therapeutic Agent for Type 2 Diabetes Mellitus"],"prefix":"10.1248","volume":"48","author":[{"given":"Hideki","family":"Nakamura","sequence":"first","affiliation":[{"name":"Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Saitama 341\u20130005, Japan"},{"name":"Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812\u20138582, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Endo","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Saitama 341\u20130005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812\u20138582, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Burge MR, Sood V, Sobhy TA, Rassam AG, Schade DS. Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes Obes. Metab<\/i>., 1<\/b>, 199\u2013206 (1999).","DOI":"10.1046\/j.1463-1326.1999.00031.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet. Med<\/i>., 25<\/b>, 245\u2013254 (2008).","DOI":"10.1111\/j.1464-5491.2007.02341.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care<\/i>, 40<\/b>, 706\u2013714 (2017).","DOI":"10.2337\/dc16-1943"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) U.K. prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. Diabetes<\/i>, 44<\/b>, 1249\u20131258 (1995).","DOI":"10.2337\/diabetes.44.11.1249"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Watanabe H, Asahara S-I, Son J, Mckimpson WM, De Cabo R, Accili D. Cyb5r3 activation rescues secondary failure to sulfonylurea but not \u03b2<\/i>-cell dedifferentiation. PLOS ONE<\/i>, 19<\/b>, e0297555 (2024).","DOI":"10.1371\/journal.pone.0297555"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tang WH. Do thiazolidinediones cause heart failure? A critical review. Cleve. Clin. J. Med<\/i>., 73<\/b>, 390\u2013397 (2006).","DOI":"10.3949\/ccjm.73.4.390"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr. Diab. Rep<\/i>., 19<\/b>, 151 (2019).","DOI":"10.1007\/s11892-019-1270-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hermann LS. Clinical pharmacology of biguanides. Oral antidiabetics<\/i>. Berlin, Heidelberg, Springer Berlin Heidelberg, pp. 373\u2013407 (1996). https:\/\/link.springer.com\/chapter\/10.1007\/978-3-662-09127-2_14.","DOI":"10.1007\/978-3-662-09127-2_14"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Meyers AG, Hudson J, Cravalho CKL, Matta ST, Villalobos-perez A, Cogen F, Chung ST. Metformin treatment and gastrointestinal symptoms in youth: findings from a large tertiary care referral center. Pediatr. Diabetes<\/i>, 22<\/b>, 182\u2013191 (2021).","DOI":"10.1111\/pedi.13148"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Asano N. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology<\/i>, 13<\/b>, 93R\u2013104R (2003).","DOI":"10.1093\/glycob\/cwg090"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. a-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care<\/i>, 28<\/b>, 154\u2013163 (2005).","DOI":"10.2337\/diacare.28.1.154"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J. Diabetes Complications<\/i>, 27<\/b>, 473\u2013478 (2013).","DOI":"10.1016\/j.jdiacomp.2013.05.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Pishdad R, Auwaerter PG, Kalyani RR. Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review. Curr. Diab. Rep<\/i>., 24<\/b>, 108\u2013117 (2024).","DOI":"10.1007\/s11892-024-01537-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nakajima H, Okada H, Kogure A, Osaka T, Tsutsumi T, Onishi M, Mitsuhashi K, Kitagawa N, Mogami S, Kitamura A, Ishii M, Nakamura N, Kishi A, Eiko S, Hamaguchi M, Fukui M. Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: the TOP-STAR study. J. Diabetes Investig<\/i>., 15<\/b>, 1809\u20131817 (2024).","DOI":"10.1111\/jdi.14314"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yao H, Zhang A, Li D, Wu Y, Wang C-Z, Wan J-Y, Yuan C-S. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ<\/i>, 384<\/b>, e076410 (2024).","DOI":"10.1136\/bmj-2023-076410"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ<\/i>, 344<\/b> (mar12 1), e1369 (2012).","DOI":"10.1136\/bmj.e1369"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet<\/i>, 352<\/b>, 854\u2013865 (1998).","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Fredriksson R, H\u00f6glund PJ, Gloriam DEI, Lagerstr\u00f6m MC, Schi\u00f6th HB. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett<\/i>., 554<\/b>, 381\u2013388 (2003).","DOI":"10.1016\/S0014-5793(03)01196-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Madiraju SRM, Poitout VG. Protein-coupled receptors and insulin secretion: 119 and counting. Endocrinology<\/i>, 148<\/b>, 2598\u20132600 (2007).","DOI":"10.1210\/en.2007-0336"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Overton HA, Fyfe MCT, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol<\/i>., 153<\/b> (Suppl. 1), S76\u2013S81 (2008).","DOI":"10.1038\/sj.bjp.0707529"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab<\/i>., 3<\/b>, 167\u2013175 (2006).","DOI":"10.1016\/j.cmet.2006.02.004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, Matsumoto S-I, Kamohara M, Hiyama H, Yoshida S, Momose K, Ueda Y, Matsushime H, Kobori M, Furuichi K. Corrigendum to \u201cLysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor\u201d. Biochem. Biophys. Res. Commun<\/i>., 326<\/b>, 744\u2013751 (2005).","DOI":"10.1016\/j.bbrc.2004.11.120"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chu Z-L, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, Moloney M, Gao H, Mondala H, Bagnol D, Unett D, Liang Y, Demarest K, Semple G, Behan DP, Leonard J. A role for \u03b2<\/i>-Cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology<\/i>, 148<\/b>, 2601\u20132609 (2007).","DOI":"10.1210\/en.2006-1608"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Chu Z-L, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in Glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology<\/i>, 149<\/b>, 2038\u20132047 (2008).","DOI":"10.1210\/en.2007-0966"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Lauffer LM, Iakoubov R, Brubaker PL. GPR119 Is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes<\/i>, 58<\/b>, 1058\u20131066 (2009).","DOI":"10.2337\/db08-1237"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Takaki R, Ono J. Preparation and culture of isolated islets and dissociated islet cells from rodent pancreas. J. Tissue Cult. Methods<\/i>, 9<\/b>, 61\u201366 (1985).","DOI":"10.1007\/BF01797776"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Semple G, Ren A, Fioravanti B, Pereira G, Calderon I, Choi K, Xiong Y, Shin YJ, Gharbaoui T, Sage CR, Morgan M, Xing C, Chu ZL, Leonard JN, Grottick AJ, Al-Shamma H, Liang Y, Demarest KT, Jones RM. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo<\/i> activity in rodent models of glucose control. Bioorg. Med. Chem. Lett<\/i>., 21<\/b>, 3134\u20133141 (2011).","DOI":"10.1016\/j.bmcl.2011.03.007"},{"key":"28","unstructured":"28) Roberts B, Karpf DB, Martin R, Lavan B, Wilson M, McWherter C. MBX-2982, a novel GPR119 agonist, shows greater efficacy in patients with the most glucose intolerance: results of a phase 1 study with an improved formulation. Diabetes<\/i>, Vol. 59, Alexandria, American Diabetes Association, pp. A164\u2013A165 (2010)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Matsumoto K, Yoshitomi T, Ishimoto Y, Tanaka N, Takahashi K, Watanabe A, Chiba K. DS-8500a, an orally available g protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. J. Pharmacol. Exp. Ther<\/i>., 367<\/b>, 509\u2013517 (2018).","DOI":"10.1124\/jpet.118.250019"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Yoshida S, Ohishi T, Matsui T, Tanaka H, Oshima H, Yonetoku Y, Shibasaki M. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db\/db mice. Biochem. Biophys. Res. Commun<\/i>., 402<\/b>, 280\u2013285 (2010).","DOI":"10.1016\/j.bbrc.2010.10.015"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Li NX, Brown S, Kowalski T, Wu M, Yang L, Dai G, Petrov A, Ding Y, Dlugos T, Wood HB, Wang L, Erion M, Sherwin R, Kelley DE. GPR119 Agonism increases glucagon secretion during insulin-induced hypoglycemia. Diabetes<\/i>, 67<\/b>, 1401\u20131413 (2018).","DOI":"10.2337\/db18-0031"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Semple G, Lehmann J, Wong A, Ren A, Bruce M, Shin YJ, Sage CR, Morgan M, Chen WC, Sebring K, Chu ZL, Leonard JN, Al-Shamma H, Grottick AJ, Du F, Liang Y, Demarest K, Jones RM. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg. Med. Chem. Lett<\/i>., 22<\/b>, 1750\u20131755 (2012).","DOI":"10.1016\/j.bmcl.2011.12.092"},{"key":"33","unstructured":"33) Roberts BR, Gregoire FM, Karpf DB, Clemens ED, Lavan B, Johnson J, Mcwherter CA, Martin R, Wilson M. MBX-2982, a novel oral GPR119 agonist for the treatment of type 2 diabetes: results of single & multiple dose studies. Diabetes<\/i>, 58<\/b>, S43 (2009)."},{"key":"34","unstructured":"34) Nunez DJ, Lewis EW, Swan S, Bush MA, Cannon C, McMullen SL, Collins DA, Feldman PL. A study in healthy volunteers to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of GSK1292263, a novel GPR119 agonist. Diabetes<\/i>, Vol. 59, American Diabetes Association, Alexandria, p. A22 (2010)."},{"key":"35","unstructured":"35) Goodman ML, Dow J, Van Vliet AA, Hadi S, Karbiche D, Lockton JA. The novel GPR119-receptor agonist PSN821 shows glucose lowering and decreased energy intake in patients with T2DM after 14 days treatment. Diabetes<\/i>, Vol. 60, American Diabetes Association, Alexandria, p. A84 (2011)."},{"key":"36","unstructured":"36) Gater D. 32Nd national medicinal chemistry symposium-medicinal chemistry developments for neurodegeneration, diabetes and cancer. IDrugs<\/i>, 13<\/b>, 514\u2013516 (2010)."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kato M, Ishizuka H, Taguchi T, Shiosakai K, Kamiyama E, Sata M, Yoshida T. Pharmacokinetics and safety of DS-8500a, an antidiabetic drug, in japanese subjects with hepatic or renal impairment: a single-center, open-label, single-dose study. Adv. Ther<\/i>., 35<\/b>, 1239\u20131250 (2018).","DOI":"10.1007\/s12325-018-0739-4"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/1\/48_b24-00737\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:29:57Z","timestamp":1738380597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/1\/48_b24-00737\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00737","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"article-number":"b24-00737"}}